Biotron Ltd has released a press release.
BIT225 Phase 2 HIV-1 Clinical Trial Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- $1.6 Million R&D Tax Rebate Received
- BIT225 Accelerates HIV-1 Virus Reduction
- Zika Virus Program Update
- Biotron compounds demonstrate activity against Zika virus
- $1.5 Million R&D Tax Rebate
Later from Biotron
- $1.6 Million R&D Tax Incentive Received
- Biotron Compounds Demonstrate Activity Against HBV
- Response to ASX Appendix 4C Query
- Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
- Significant Immunological Outcomes in BIT225 HIV-1 Trial
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron